Ipilimumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ipilimumab |
| DrugBank ID | DB06186 |
| Brand Names (EU) | Yervoy |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.33% |
Approved Indication (EMA)
MelanomaYervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). Yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimu
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | metastatic melanoma | 99.33% | DL |
| 2 | choroideremia | 99.06% | DL |
| 3 | non-cutaneous melanoma | 99.02% | DL |
| 4 | epithelioid cell melanoma | 98.96% | DL |
| 5 | eyelid melanoma | 98.95% | DL |
| 6 | scrotum melanoma | 98.84% | DL |
| 7 | nodular malignant melanoma | 98.64% | DL |
| 8 | malignant melanoma of the mucosa | 98.64% | DL |
| 9 | acral lentiginous melanoma (disease) | 98.64% | DL |
| 10 | lentigo maligna melanoma | 98.64% | DL |
| 11 | balloon cell malignant melanoma | 98.64% | DL |
| 12 | amelanotic skin melanoma | 98.64% | DL |
| 13 | CDK4 linked melanoma | 98.64% | DL |
| 14 | superficial spreading melanoma | 98.64% | DL |
| 15 | choroidal dystrophy, central areolar | 98.45% | DL |
| 16 | intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency | 98.34% | DL |
| 17 | male infertility due to gonadal dysgenesis | 94.46% | DL |
| 18 | 46,XY disorder of gonadal development | 94.26% | DL |
| 19 | gonadal dysgenesis | 89.82% | DL |
| 20 | severe combined immunodeficiency due to LCK deficiency | 87.02% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.